At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 84 enrolled

Drug / intervention

700 mg IV +3 moredrug

Likely dose

700 mg IVfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00867100

NCT00867100Phase 1Completed

A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

Bausch Health Americas, Inc.·interventional·Posted Mar 23, 2009·Updated Jan 16, 2019

In Brief

A Phase 1 clinical trial evaluating 700 mg IV, 350 mg SC, and 2 other interventions for Psoriasis. Completed, enrolled 84 participants.

This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPsoriasis

Countries--

Collaborators--

Phase 1CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 2007

First PostedMar 2009

Primary CompletionSep 2009

TodayJul 2026

First PostedMar 23, 2009

Enrollment StartDec 1, 2007

Primary CompletionSep 1, 2009

TodayJul 2, 2026

Enrollment to primary: 1.8 yearsPosted 17.3 years ago

700 mg IVdrug

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

350 mg SCdrug

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Placebodrug

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

140 mg SCdrug

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).